Amundi Pioneer Asset Management Inc. Takes $148,000 Position in Global Blood Therapeutics Inc (GBT)

Amundi Pioneer Asset Management Inc. bought a new stake in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,600 shares of the company’s stock, valued at approximately $148,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of GBT. Lindbrook Capital LLC bought a new stake in shares of Global Blood Therapeutics in the 4th quarter worth about $55,000. Bank of Montreal Can lifted its holdings in shares of Global Blood Therapeutics by 61.9% in the 4th quarter. Bank of Montreal Can now owns 1,582 shares of the company’s stock worth $65,000 after acquiring an additional 605 shares during the last quarter. Strs Ohio bought a new stake in shares of Global Blood Therapeutics in the 4th quarter worth about $65,000. Focused Wealth Management Inc lifted its holdings in shares of Global Blood Therapeutics by 14.6% in the 4th quarter. Focused Wealth Management Inc now owns 3,140 shares of the company’s stock worth $129,000 after acquiring an additional 400 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Global Blood Therapeutics by 740.3% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the company’s stock worth $165,000 after acquiring an additional 3,835 shares during the last quarter.

Shares of NASDAQ:GBT traded up $1.34 during trading hours on Friday, hitting $55.18. The company’s stock had a trading volume of 648,509 shares, compared to its average volume of 640,554. Global Blood Therapeutics Inc has a 52 week low of $30.15 and a 52 week high of $59.95. The firm has a market cap of $3.11 billion, a P/E ratio of -16.18 and a beta of 2.10.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Wednesday, February 27th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.05). During the same quarter last year, the company posted ($0.95) EPS. Sell-side analysts expect that Global Blood Therapeutics Inc will post -3.9 EPS for the current fiscal year.

GBT has been the subject of several analyst reports. BidaskClub upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Guggenheim assumed coverage on shares of Global Blood Therapeutics in a report on Friday, February 22nd. They set a “buy” rating and a $75.00 price objective for the company. Zacks Investment Research lowered shares of Global Blood Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, March 4th. HC Wainwright set a $150.00 price objective on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Friday, April 12th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and set a $75.00 price objective on shares of Global Blood Therapeutics in a report on Thursday, February 28th. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $87.85.

COPYRIGHT VIOLATION WARNING: “Amundi Pioneer Asset Management Inc. Takes $148,000 Position in Global Blood Therapeutics Inc (GBT)” was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/3600-shares-in-global-blood-therapeutics-inc-gbt-acquired-by-amundi-pioneer-asset-management-inc.html.

Global Blood Therapeutics Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Featured Article: How to interpret the current ratio

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.